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Background: To determine the protein expression profile (PEP) of primary and recurrent ovarian cancer patients in
order to predict therapeutic targets for chemotherapy.
Methods: Tissue samples were submitted for PEP in two formats, including formalin-fixed paraffin-embedded tissue
for immunohistochemistry (IHC) and fresh frozen tissue for oligonucleotide microarray (MA) gene expression assays.
Specimens were analyzed for 18 protein markers and 88 MA genes. A series of Generalized Linear Models (GLM)
was used to predict the proportion of positive results by histology for each biomarker.
Results: Four hundred and twenty-eight specimens were analyzed for IHC and 67 specimens for MA analysis. The
majority of specimens, 82%, were serous histology and 35.3% of specimens were poorly differentiated. Sixty percent
of specimens were advanced stage, 62% were from a primary diagnosis, and 53% were obtained from a metastatic
site. BCRP, ER, MGMT, and RRM1 proteins were overexpressed in 85%, 47%, 93%, and 47% of serous carcinomas,
respectively. The MGMT and RRM1 biomarkers were significantly overexpressed in serous (p < .001) and endometrioid
(p = .01) histologies when compared to clear cell histology. MGMT was significantly elevated in 93% of serous
and endometrioid samples, compared to 62% of samples with clear cell histology. Those proteins most often
underexpressed included Her2/neu, SPARC, and c-kit, seen in less than 1%, 4%, and 5% of specimens, respectively.
Conclusions: PEP is a reliable and effective way of analyzing ovarian cancer specimens. PEP target identification does
not appear to vary significantly with site evaluated, ovarian or other abdominal pelvic tissue, or primary versus
recurrent disease. Variability in the expression of drug targets, including BCRP, ER, MGMT, and RRM1 could impact
decision making pertaining to which therapeutic strategies carry the best chances for controlling disease.
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Ovarian cancer is the fifth-leading cause of cancer death
among women in the United States [1]. The current
standard initial treatment of epithelial ovarian cancer
includes surgical staging with optimal tumor debulking,
followed by the administration of six cycles of intraven-
ous chemotherapy with carboplatin and placlitaxel [2].
Although more than 80% of patients benefit from first-line
therapy, tumor recurrence develops in nearly all patients,
at a median of 15 months from completion of treatment* Correspondence: john.farley@chw.edu
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unless otherwise stated.[2]. Moreover, platinum resistance occurs in 25% of
patients within 6 months from the last administration of
platinum-agent [3], and the overall five-year survival rate
of advanced stage disease is 37% [1]. For this reason, ovar-
ian cancer is considered a systemic disease, and systemic
therapies are being increasingly relied upon for treatment.
In the recurrent setting, tumor molecular profiling has
been an area of recent investigation in an attempt to
improve patient outcomes by employing targeted che-
motherapeutic agents. In a pilot study, Von Hoff et al.
[4] performed molecular profiling (MP) in 86 patients
with refractory metastatic cancers. Of the 27% of patients
who received targeted chemotherapy, the MP approach
resulted in a longer progression-free survival than the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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progression.
In another study, The Cancer Genome Atlas (TCGA)
researchers reported DNA gene mutations on tumor sam-
ples in patients with high-grade serous ovarian carcinomas
(HGS-OvCa) [3]. Their findings were significant for TP53
mutations being identified in nearly all tumors (96%),
while BRCA1 and BRCA2 mutations were identified in
22% of tumors. Their results indicated that the mutational
spectrum of HGS-OvCa is distinct from other histological
subtypes of ovarian cancer. Further study would therefore
warrant the investigation of targeted therapies based on
the specific molecular alterations identified in a specific
histology of ovarian cancer.
To date, there is modest data regarding MP of ovarian
cancer specimens. Of the 86 patients in the Von Hoff
study, only 5 had ovarian cancer [4]. Furthermore, the
TCGA data was limited to specimens with high-grade
serous histology. The objective of the current study,
therefore, is to determine the protein expression profile
of primary and recurrent ovarian cancer patients of all
histological types in order to predict potential therapeutic
targets for chemotherapy.
Methods
The Target Now® (Caris Life Sciences®) database was
accessed to obtain MP results for ovarian cancer tissue
samples. De-identified results of Target Now®, as well as
available histopathologic and clinical data from the Caris
Life Sciences'® database were obtained after Institutional
Review Board (IRB) approval. Because the research involved
data collected previously for clinical utility (non-research
purposes), this study qualified and was approved for expe-
dited review by the IRB at St. Joseph’s Hospital and Medical
Center. Data was transferred from Caris Life Sciences® to
the investigators in the form of a limited data set in com-
pliance with a Data Transfer Agreement.
Immunohistochemistry
The database was used to analyze formalin fixed tissue
samples for protein expression profile (PEP) by immuno-
histochemistry (IHC), which were obtained from women
with primary and recurrent ovarian carcinoma, 62% and
37% respectively. Specimens were collected between
January 2010 and December 2010. A total of 428 specimens
were analyzed for 18 protein markers specific to the Target
Now® PEP: Androgen Receptor, BCRP, c-kit, ER/PR,
ERCC1, Her2/Neu, MGMT, MRP1, PDGFR, PGP, PTEN,
RRM1, SPARC, TOP2A, TOPO1, TS, cMET, TUBB3.
Analyses were performed by Caris Life Sciences® (Irving,
Tx). The tests performed by Caris Life Sciences® were part
of the Target Now® MP service. Staining protocols employed
the Ventana Medical Systems, Inc. (Tucson, AZ) automated
staining systems. Following heat-induced epitope retrieval,antibody incubation was for 20–40 minutes (antibody-spe-
cific), and visualization procedure was based on the staining
system. Appropriate positive and negative control speci-
mens and slides were included for all of the proteins tested.
Slides were evaluated semi-quantitatively for staining inten-
sity on a scale of 0 (no staining) to 3 and by the percentage
of the tumor cells showing the reactivity. For IHC scoring
appropriate positive and negative thresholds were defined
and considered in the subsequent statistical analyses with
intermediate and unknown results considered not evalu-
able. Comparison of IHC results with clinical variables was
performed with Fisher’s exact test.
Oligonucleotide microarray (MA) gene expression
A total of 67(25%) of the 264 primary specimens were an-
alyzed for MA. Normal tissue from the abdominal pelvic
cavity was used as a control organ. No specific site was
ever designated as a control, the only requirement being
that it was uninvolved with cancer. The arrays contain
probes for 88 genes for which there is a therapeutic agent
that could potentially interact with that gene. Those 88
genes are listed in Additional file 1: Table S1. The frozen
tumor fragments for MA were placed in a glass tube on
0.5 mL of frozen 0.5 M guanidine isothiocyanate solution,
thawed, and homogenized with a Covaris S2 (Covari,
Woburn, MA). RNA was bound and then eluted. RNA
was tested for integrity by assessing the ratio of 28S to 18S
ribosomal RNA on an Agilent BioAnalyzer (Agilent, Santa
Clara, CA). Tumor RNA (2 to 5 μg) and control RNA
from a sample of a normal tissue representative of the
tumor's tissue of origin (2 to 5 μg) were converted to
cDNA and labeled during T7 polymerase amplification
with contrasting fluor tagged (Cy3, Cy5) cytidine triphos-
phate. The labeled tumor and its tissue of origin reference
were hybridized to an Agilent H1Av2 60-mer oligo array
chip with 17,085 unique probes. The chips were then
scanned on an Agilent Microarray Scanner (Agilent, Santa
Clara, CA). Fluorescence intensity data were extracted,
normalized, and analyzed using Agilent Feature Extraction
Software. The MA was considered positive for a target if
the difference in expression for a gene between tumor and
control organ tissue was at a significance level of P ≤ .001.
Cut points were chosen for gene expression of the cancer
based on stringent P values (P < .001) compared with the
normal mRNA expression levels. It was decided that using
the mRNA level from the tissue of the organ of tumor
origin would be the most informative comparison. To
provide stringent quality control, these MA studies
were performed in a Clinical Laboratory Improvement
Amendments–certified environment.
Statistical analysis
Generalized Linear Models (GLM) were used with bino-
mial distribution and link logit specified to predict the
Foss et al. Gynecologic Oncology Research and Practice 2014, 1:4 Page 3 of 8
http://www.gynoncrp.com/content/1/1/4dichotomous outcome variable overexpression from the
categorical predictor histology. Histologies classified as
other was set as the reference group for the computation
of parameter estimate odds ratios. One GLM model per
biomarker was conducted resulting in eighteen models.
The False Discovery Rate (SITE) correction used to adjust
for multiple comparisons for significant GLM models.
SPSS version 20 was used for statistical analyses.
Results
Specimens were obtained from 428 females with a median
age of 62 years (Table 1). The majority of specimens ana-
lyzed by IHC were of serous and carcinoma histology
(82%, Table 2). Thirty-five percent of specimens were
poorly differentiated, while 27% were of unknown histo-
logical grade. Of the primary specimens, 62% were from
adnexa, while 53% were obtained from a metastatic site
and not the adnexa. Of the 67 specimens analyzed by MA,
55 (82%) were serous histology, 4 (6%) endometrioid, 2
(3%) clear cell, and 6 (9%) other. An advanced-stage diag-
nosis was represented in 60% of specimens. Five of the
eighteen binomial GLM models predicting protein overex-
pression were significant. Significant models were for
BCRP, ER, MGMT, RRM1, and PTEN at the trend levelTable 1 Patient characteristics at diagnosis
(N) Percent%
TOTAL 428
Median age (years) 61.7
Tumor histology
Serous 351 82










Well differentiated 117 27
Moderately differentiated 43 10





Unknown 7 1(Table 3). Twelve pairwise post hoc comparisons were
performed for each significant model resulting in sixty
post hoc contrasts (Table 4).
ER protein was significantly overexpressed in 47% of
serous and 50% of endometrioid samples, while only
elevated in only 14% of clear cell samples. Post-hoc
testing demonstrated the ER protein was significantly over-
expressed in serous (p < .001) and endometrioid (p = .003)
histologies when compared to clear cell histology (Table 2).
The MGMT and RRM1 biomarkers were also significantly
overexpressed in serous (p < .001) and endometrioid
(p = .01) histologies when compared to clear cell histology.
MGMT was significantly elevated in 93% of serous and
endometrioid samples, compared to 62% of samples with
clear cell histology. Only 14% of clear cell samples were
found to have overexpression of RRM1, compared to 47%
of serous and 25% of endometrioid samples. Those pro-
teins most often underexpressed included Her2/neu,
SPARC, and c-kit, seen in less than 1%, 4%, and 5% of
specimens, respectively. None of the post hoc compari-
sons for histology were significant for biomarkers BCRP
and PTEN with the FDR correction applied.
There were 88 genes evaluated by MA gene expression
and included in statistical analysis for association with
histology. Those genes most overexpressed, defined as a
difference in expression of mRNA between tumor and
control organ tissue at a significance level of P ≤ .001, in
serous histology included TOP2A, MSH2, OGFR, RRM2,
GART, and PARP1. A description of proportion of positive
expression is shown in Figure 1. There were fourteen
genes that were never expressed in serous histology and
are not shown in Figure 1: ABCG2, AR, CES2, KIT,
MS4A1, PDGFRA, PDGFRB, POLA1, RXRB, SPARC,
SSTR1, SSTR2, SSTR4, and TOP1. There was no differ-
ence in protein or gene overexpression identified when
analyzed by age, FIGO stage, grade, primary or recurrent
tumor, and ovary or other biopsy site.
Discussion
TCGA project has analyzed post-transcriptional messenger
RNA expression, microRNA expression, promoter methyla-
tion, and DNA copy number in 489 high-grade serous
ovarian adenocarcinomas [3]. They reported that high-
grade serous ovarian cancer is characterized by TP53 mu-
tations in almost all tumors (96%); and a low prevalence
but statistically significant recurrent somatic mutations in
nine further genes including NF1, BRCA1, BRCA2, RB1,
and CDK12. Pathway analyses suggested that homologous
recombination was a potentially important pathway and
was defective in about half of the high grade serous
cancers analyzed. NOTCH and FOXM1 signaling were
involved in serous ovarian cancer pathophysiology.
Molecular PEP is a powerful approach to identify clinical
markers for diagnosis and prognosis as in epithelial ovarian
Table 2 Counts and proportions of overexpression for biomarkers by histology
Biomarker Serous mean (sd) Clear cell mean (sd) Endometrioid mean (sd) Other mean (sd)
1 Androgen receptor .27(.44) .10(.31) .27(.45) .12(.33)
2 BCRP* .85(.36) .85(.37) .65(.49) .72(.46)
3 c-kit .05(.22) .00(.00) .00(.00) .00(.00)
4 ER* .47(.50) .14(.36) .50(.51) .39(.50)
5 ERCC1 .24(.43) .33(.48) .04(.19) .25(.44)
6 Her2/Neu .01(.09) .00(.00) .00(.00) .00(.00)
7 MGMT*** .93(.25) .62(.50) .93(.26) .89(.32)
8 MRP1 .89(.32) .85(.37) .92(.27) .92(.27)
9 PDGFR .18(.38) .15(.37) .23(.43) .16(.37)
10 PGP .19(.39) .24(.47) .21(.42) .14(.36)
11 PR .39(.49) .19(.40) .50(.51) .36(.49)
12 PTEN .65(.48) .48(.51) .43(.50) .61(.50)
13 RRM1** .47(.50) .14(.36) .24(.44) .57(.50)
14 SPARC MONO .11(.32) .24(.47) .10(.30) .16(.37)
15 SPARC POLY .04(.20) .00(.00) .00(.00) .00(.00)
16 TOP2A .39(.49) .20(.41) .23(.43) .40(.50)
17 TOPO1 .89(.32) .86(.36) .89(.32) .93(.26)
18 TS .15(.35) .05(.22) .08(.27) .16(.37)
*P < .05, **P < .01, ***P < .001.
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of 244 serous tumors of different grades (0–3) and stages
(I–IV) was evaluated by comprehensive IHC for proteins
not necessarily associated with response to selective che-
motherapeutic agents [5]. Ccne1, Ran, Cdc20, and Cks1
showed significant differences of expression in association
with the clinical stage of disease. The application of theseTable 3 Parameter estimates predicting overexpression from
OR
BCRP Carcinoma and serous 2.21
Clear cell 2.2
Endometriod 0.735
ER Carcinoma and serous 1.39
Clear Cell 0.26
Endometriod 1.55
MGMT Carcinoma and serous 1.64
Clear cell 0.2
Endometriod 1.56
PTEN Carcinoma and serous 1.19
Clear cell 0.59
Endometriod 0.49
RRM1 Carcinoma and serous 0.67
Clear cell 0.13
Endometriod 0.25biomarkers in both the initial diagnosis and prognostic at-
tributes of patients with epithelial ovarian tumors could
prove to be useful in patient management.
The main objective of this study was to characterize
and identify the characteristics of epithelial ovarian cancers
through PEP of ovarian tumors in order to predict targeted
therapies. The current study is one of the largest PEPhistology
95% CI P Wald chi-square
.88-5.58 0.09 8.39, p = .039
.49-9.94 0.3
.22-2.41 0.61
.63-3.05 0.42 7.76, p = .051
.06-1.09 0.07
.54-4.46 0.42
.46-5.81 0.48 18.57, p < .001
.04-.86 0.03
.24-10.14 0.64
.54-2.61 0.67 7.01, p = .071
.19-1.85 0.36
.17-1.41 0.18
.31-1.46 0.32 13.06, p = .005
.03-.52 0.004
.08-.78 0.017
Table 4 Post hoc comparisons for significant glm models predicting overexpression
BCRP ER
Mean diff SE 95% LCL 95% UCL p Mean diff SE 95% LCL 95% UCL p
Carcinoma and serous Clear cell 0 0.08 −0.16 0.16 .993 0.33 0.08 0.17 0.49 .000*
Carcinoma and serous Endometriod 0.2 0.10 0.01 0.38 .039 −0.03 0.10 −0.22 0.17 .783
Carcinoma and serous Other 0.13 0.09 −0.05 0.31 .155 0.08 0.10 −0.11 0.27 .405
Clear cell Endometriod 0.2 0.12 −0.04 0.44 .110 −0.36 0.12 −0.60 −0.12 .003*
Clear cell Other 0.13 0.12 −0.11 0.37 .279 −0.25 0.12 −0.48 −0.02 .037
Endometriod Other −0.07 0.13 −0.32 0.19 .609 0.11 0.13 −0.15 0.37 .417
MGMT RRM1
Mean diff SE 95% LCL 95% UCL p Mean diff SE 95% LCL 95% UCL p
Carcinoma and serous Clear cell 0.31 0.11 0.10 0.52 0.00* 0.33 .081 .17 .49 .000*
Carcinoma and serous Endometriod 0.00 0.05 −0.10 0.10 0.95 0.22 .086 .05 .39 .010*
Carcinoma and serous Other 0.04 0.06 −0.08 0.16 0.52 -.10 .097 -.29 .09 .311
Clear cell Endometriod −0.31 0.12 −0.54 −0.08 0.00* -.11 .112 -.33 .11 .338
Clear cell Other −0.27 0.12 −0.51 −0.04 0.02 −0.43 .121 -.67 -.19 .000*
Endometriod Other 0.04 0.08 −0.11 0.18 0.95 −0.32 .124 -.56 -.08 .010*
PTEN
Mean diff SE 95% LCL 95% UCL p
Carcinoma and serous Clear cell .17 .112 -.05 .39 .128
Carcinoma and serous Endometriod 0.22 .097 .03 .41 .024
Carcinoma and serous Other .04 .096 -.15 .23 .679
Clear cell Endometriod .05 .144 -.23 .33 .740
Clear cell Other -.13 .143 -.41 .15 .359





















Figure 1 Proportion of protein overexpression by gene for serous ovarian cancer. The figure reports the fraction of serous ovarian cancer
samples with overexpressed mRNA by gene. There was no differential expression of genes with regard to stage, grade, or race.
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study demonstrates that PEP is a reliable and effective way
of analyzing ovarian cancer specimens. In this study,
protein expression target identification did not appear
to vary significantly with the site evaluated, ovarian or
other abdominal pelvic tissue, or with primary versus
recurrent disease.
Several markers have been identified which may predict
a specific tumor’s response to chemotherapy (Table 3).
Breast cancer resistance protein (BCRP), an atypical drug
efflux pump, mediates multidrug resistance in breast can-
cer, as well as other cancer types, by reducing the intracel-
lular concentration of cytotoxic drugs [6]. BCRP has been
described in breast, colon, gastric cancer, and fibrosar-
coma cell lines but has also had documented overex-
pression in ovarian cancer cell lines [7]. Studies in
topotecan-resistant ovarian cancer cell lines have dem-
onstrated a substantial overexpression of BCRP. More-
over, these cell lines demonstrated resistance to other
topoisomerase I inhibitors, SN-38 (the active metabolite of
irinotecan, and 9-aminocamptothecin, as well as the
topoisomerase II inhibitor, mitoxantrone [6,7]). Topotecan,
etoposide, mitoxantrone, 5-FU, anthracyclines such as
doxorubicin and pirarubicin, as well as methotrexate
have all been identified as substrates of BCRP [8,9], and
therefore would be less effective in tumors that overex-
press this protein. However, paclitaxel, vincristine, vin-
desine, mitomycin c, and cisplatin are not mediated by
BCRP [9] and would likely be more successful in treat-
ing patients with tumors that overexpress BCRP.
Tumors which overexpress estrogen receptor (ER) may
have an enhanced response to anti-estrogens such as
megestrol, tamoxifen, and aromatase inhibitors. These
therapies have been used extensively in the treatment of
ER-positive breast cancer. However, there is sparse dataon ER-positivity in ovarian tumors. In the ‘MALOVA’
Ovarian Cancer Study, the investigators identified that ER
was expressed in 36% of epithelial ovarian tumors [10].
The authors suggested ER is a prognostic indicator of
improved survival in ovarian cancer patients, though no
targeted therapy was used in this study. Data on the use of
anti-estrogens in the treatment of ovarian cancer is limited
to phase II trials with results indicating these therapies,
if successful, are predominantly able to achieve disease
stabilization, with only marginal rates of partial or complete
treatment responses [11-15].
MGMT, or O6-methlyguanine-DNA methyltransferase,
is an enzyme that repairs methylated DNA and plays a
crucial role in the protection against alkylating agents
[16,17]. MGMT expression in cancer cells can inhibit the
success of chemotherapy treatment with alkylating agents,
which work by triggering DNA methylation [18]. If MGMT
is overexpressed in the tumor, alkylating agents such as
temozolomide may be less effective. Low expression of
MGMT has been associated with successful response to
treatment with temozolomide [19]. Furthermore, inhibition
of MGMT activity has been shown to increase the toxicity
of alkylating agents [17,18].
RRM1 is a subunit of Ribonucleotide reductase (RR),
an enzyme that acts as the rate-limiting step in DNA syn-
thesis, as it is the only known enzyme to convert ribonu-
cleotides to deoxyribonucleotides for DNA polymerization
and repair. It functions with the p53-regulated RRM2
homologue p53R2 and is important in DNA repair sec-
ondary to genotoxic stress [20]. Gemcitabine is an analog
of deoxycytidine and is converted intracellularly into
active diphosphate and triphosphate nucleosides, which
become incorporated into the DNA chain, leading to
termination of chain elongation and inhibition of DNA
synthesis [21]. In preclinical studies, increased RRM1
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gemcitabine resistance, suggesting that RRM1 expression
is a negative predictor of gemcitabine efficacy [20-24].
However, patients with low as compared to high levels of
tumoral RRM1 expression had improved survival when
treated with gemcitabine-based therapy [25].
In this particular study, BCRP, ER, MGMT, and RRM1
proteins were overexpressed in 85%, 47%, 93%, and 47%
of serous carcinomas, respectively. As these proteins have
been shown to be associated with various resistances to
specific chemotherapeutic agents, targeted therapy may be
helpful in identifying successful treatments. Because of the
increased expression of BCRP, MGMT, and RRM1 identi-
fied in serous carcinomas, in theory chemotherapeutic
agents such as etoposide, adriamycin, temozolomide, and
gemcitabine may be avoided in the treatment of serous tu-
mors that overexpress these biomarkers and considered
only for other histologies of ovarian cancer.
On the other hand, for a segment of the ovarian cancer
population, drugs that have not been developed in ovarian
cancer, such as temozolomide, could be useful for patients
with the right biomarker profile, such as low MGMT ex-
pression, perhaps even in preference to giving a standard
drug like topotecan to a patient with suboptimal biomarker
expression, such as low TOPO1. In this way, PEP offers a
laboratory-based approach to drug selection, rather than the
empiric method of selecting drugs blindly. Accordingly, PEP
could impact medical decision-making by prioritizing which
standard agents are most likely and least likely to offer bene-
fit to the individual patient, as well as identifying drugs out-
side the standard armamentarium with previously
unrecognized potential to control disease. Admittedly, future
studies measuring outcomes in patients undergoing PEP are
sorely needed before PEP becomes a standard of care.
This study is limited by its retrospective design and de-
scriptive nature, and the absence of clinical information such
as response rates, disease status, which might allow correl-
ation with response at this time. Another limitation of the
current study pertains to the absent inclusion of a variety of
molecular markers that appear to play a significant role in
driving malignant behavior or in producing drug resistance.
These include P53 and PIK3CA mutation, cMET, NOTCH,
and FOXM1. To the extent that pathways that cause che-
motherapeutic resistance were not assayed, the report of op-
timal protein expression for a given patient could over-
estimate the chance for benefit from the associated agent.
Conclusion
We observed that a majority of patients with serous
histology demonstrated protein expression associated
with resistance to one or more chemotherapeutic agents.
Furthermore, the resistance pattern in each individual
cancer was unpredictable. Future studies could include
clinical benefit analysis of MP in ovarian cancer patientsin prospective trials or analysis of MA gene expression
in ovarian tumors. Given the high proportion of ad-
vanced stage at diagnosis and the proclivity of ovarian
cancer recurrence, efforts such as MP have the potential
to make a large impact on survival of this disease.
Additional file
Additional file 1: Pairing of Protein Expression Profile (PEP) with Agents.
Competing interests
The authors disclose that they have no financial relationships and/or
competing interests.
Authors’ contributions
CF drafted manuscript, HD assisted id data acquisition and manuscript
drafting, BM reviewed manuscript, manuscript concept, DC data acquisition
manuscript review, JF manuscript concept, manuscript draft and editing. All
authors read and approved the final manuscript.
Acknowledgement
The authors wish to recognize Caris Life Sciences® staff Nancy Doll, RN, CTR
and Diane Stapleton, CTR, for data extraction and quality control as well as
Sheri Sanders, RN, BSN, MBA for administrative and operational oversight.
The authors also wish to thank Daniele A. Sumner, BA, and Angela Barber for
their assistance in editing this manuscript. The authors are solely responsible
for the content of this manuscript.
Author details
1Division of Gynecologic Oncology, Department of Obstetrics and
Gynecology, University of Arizona Cancer Center, 500 W. Thomas Road, Suite
600, Phoenix, AZ 85013, USA. 2Creighton University School of Medicine at
Dignity Health St. Joseph's Hospital and Medical Center, 500 W. Thomas
Road, Suite 600, Phoenix, AZ 85013, USA. 3Department of Gynecologic
Oncology and Reproductive Medicine, The University of Texas MD Anderson
Cancer Center, Houston, TX, USA.
Received: 20 February 2014 Accepted: 15 April 2014
Published: 30 September 2014
References
1. Siegel R, Naishadham D, Jemal A: Cancer Statistics 2013. CA Cancer J Clin
2013, 63:11–30.
2. Hennessy BT, Coleman RL, Markman M: Ovarian Cancer. Lancet 2009,
374:1371–1382.
3. The Cancer Genome Atlas Research Network: Integrated genomic analyses
of ovarian carcinoma. Nature 2011, 474:609–614.
4. Von Hoff DD, Stephenson JJ, Rosen P, Loesch DM, Borad MJ, Anthony S, Jameson
G, Brown S, Cantafio N, Richards DA, Fitch TR, Wasserman E, Fernandez C, Green S,
Sutherland W, Bittner M, Alarcon A, Mallery D, Penny R: Pilot study using
molecular profiling of patient’s tumors to find potential targets and select
treatments for their refractory cancers. J Clin Onc 2010, 28:4877–4883.
5. Ouellet V, Guyot MC, Le Page C, Filali-Mouhim A, Lussier C, Tonin PN, Provencher
DM, Mes-Masson AM: Tissue array analysis of expression microarray candidates
identifies markers associated with tumor grade and outcome in serous
epithelial ovarian cancer. Int J Cancer 2006, 119:599–607.
6. Jia P, Wu X, Li F, Xu Q, Wu M, Chen G, Liao G, Wang S, Zhou J, Lu Y, MA D:
Breast cancer resistance protein-mediated topotecan resistance in
ovarian cancer cells. Int J Gynecol Cancer 2005, 15:1042–1048.
7. Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC,
Ruevekamp-Helmers MC, Floot BG, Schellens JH: Overexpression of the
BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.
Cancer Res 1999, 59:4559–4563.
8. Mao Q, Unadkat JD: Role of the breast cancer resistance protein (ABCG2)
in drug transport. AAPS J 2005, 7:E118–E133.
9. Yuan J, Lv H, Peng B, Wang C, Yu Y, He Z: Role of BCRP as a biomarker for
predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother
Pharmacol 2009, 63:1103–1110.
Foss et al. Gynecologic Oncology Research and Practice 2014, 1:4 Page 8 of 8
http://www.gynoncrp.com/content/1/1/410. Hogdall EV, Christensen L, Hogdall CK, Blaakaer J, Gayther S, Jacobs IJ,
Christensen IJ, Kjaer SK: Prognostic value of estrogen receptor and
progesterone receptor tumor expression in Danish ovarian cancer patients:
from the ‘MALOVA’ Ovarian Cancer Study. Oncol Rep 2007, 18:1051–1059.
11. Pan Y, Kao MS: Endometrioid ovarian carcinoma benefits from aromatase
inhibitors: case report and literature review. Current Oncol 2010, 17:82–85.
12. Bowman A, Gabra H, Langdon SP, Lessells A, Stewart M, Young A, Smyth JF:
CA125 response is associated with estrogen receptor expression in a
phase II trial of letrozole in ovarian cancer: identification of an
endocrine-sensitive subgroup. Clin Cancer Res 2002, 8:2233–2239.
13. del Carmen MG, Fuller AF, Matulonis U, Horick NK, Goodman A, Duska LR,
Penson R, Campos S, Roche M, Seiden MV: Phase II trial of anastrozole in
women with asymptomatic Mullerian cancer. Gynecol Oncol 2003, 91:596–602.
14. Papadimitriou CA, Markaki S, Siapkaras J, Viachos G, Efstathiou E, Grimani I,
Hamilos G, Zorzou M, Dimopoulos MA: Hormonal therapy with letrozole
for relapsed epithelial ovarian cancer. Long-term results of a phase II
study. Oncology 2004, 66:112–117.
15. Smyth JF, Gourley C, Walker G, MacKean MJ, Stevenson A, Williams AR,
Nafussi AA, Rye T, Rye R, Stewart M, McCurdy J, Mano M, Reed N, McMahon
T, Vasey P, Gabra H, Landon SP: Antiestrogen therapy is active in selected
ovarian cancer cases: the use of letrozole in estrogen-receptor positive
patients. Clin Cancer Res 2007, 13:3617–3622.
16. Kaina B, Christmann M, Naumann S, Roos WP: MGMT: key node in the
battle against genotoxicity, carcinogenicity and apoptosis induced by
alkylating agents. DNA Repair (Amst) 2007, 6:1079–1099.
17. Casorelli I, Russo MT, Bignami M: Role of mismatch repair and MGMT in
response to anticancer therapies. Anticancer Agents Med Chem 2008,
8:368–380.
18. Gerson SL: Clinical relevance of MGMT in the treatment of cancer. J Clin
Oncol 2002, 20:2388–2399.
19. McCormack AI, McDonald KL, Gill AJ, Clark SJ, Burt MG, Campbell KA,
Braund WJ, Little NS, Cook RJ, Grossman AB, Robinson BG, Clifton-Bligh RJ:
Low O-6-methylgaunine-DNA methyltransferase (MGMT) expression and
response to temozolomide in aggressive pituitary tumours. Clin
Endocrinol (Oxf ) 2009, 71:226–233.
20. Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA: An
increase in the expression of ribonucleotide reductase large subunit 1 is
associated with gemcitabine resistance in non–small cell lung cancer
cell lines. Cancer Res 2004, 64:3761–3766.
21. Zhao LP, Xue C, Zhang JW, Hu ZH, Zhao YY, Zhang J, Huang Y, Zhao HY,
Zhang L: Expression of RRM1 and its correlation with sensitivity to
gemcitabine-based chemotherapy in advanced nasorpharyngeal carcinoma.
Chin J Cancer 2012, 31:476–483.
22. Bergman AM, Eijk PP, van Haperen VW R, Smid K, Veerman G, Hubeek I, van
den Ijssel P, Ylstra B, Peters GJ: In vivo induction of resistance to
gemcitabine results in increased expression of ribonucleotide reductase
subunit M1 as the major determinant. Cancer Res 2005, 65:9510–9516.
23. Bepler G, Kusmartseva I, Sharma S, Gautam A, Cantor A, Sharma A, Simon G:
RRM1 modulated in vitro and in vivo efficacy of gemcitabine and
platinum in non–small-cell lung cancer. J Clin Oncol 2006, 24:4731–4737.
24. Nakahira S, Nakamori S, Tsujie M, Takahashi Y, Okami J, Yoshioka S, Yamasaki
M, Marubashi S, Takemasa I, Miyamoto A, Takeda Y, Nagano H, Dono K,
Umeshita K, Sakon M, Monden M: Involvement of ribonucleotide
reductase M1 subunit overexpression in gemcitabine resistance of
human pancreatic cancer. Int J Cancer 2007, 120:1355–1363.
25. Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C,
Provencio M, Isla D, Taron M, Diz P, Artal A, Spanish Lung Cancer Group:
Ribonucleotide reductase mRNA expression and survival in gemcitabine/
cisplatin-treated advanced non-small-cell lung cancer patients.
Clin Cancer Res 2004, 10:1318–1325.
doi:10.1186/2053-6844-1-4
Cite this article as: Foss et al.: Protein profiling of ovarian cancers by
immunohistochemistry to identify potential target pathways.
Gynecologic Oncology Research and Practice 2014 1:4.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
